Digestive Diseases and Sciences

, Volume 48, Issue 3, pp 431–441 | Cite as

Spasmolytic Polypeptide-Expressing Metaplasia (SPEM) Associated with Gastric Cancer in Iceland

  • Anna Margrét Halldórsdóttir
  • Margrét Sigurdardóttir
  • Jón Gunnlaugur Jónasson
  • Margrét Oddsdóttir
  • Jónas Magnússon
  • Jeffrey R. Lee
  • James R. Goldenring


Recent studies have described a spasmolytic polypeptide-expressing metaplastic cell lineage (SPEM) in the gastric fundic mucosa associated with both chronic H. pylori infection and gastric adenocarcinoma. We investigated the association of SPEM both with early gastric adenocarcinoma and in biopsies taken from patients prior to diagnosis of cancer. Two cohorts were examined. First, gastric resections from 29 patients with early gastric cancer were examined. Second, biopsies taken from 18 patients prior to the diagnosis of gastric cancer were compared with their respective resection specimens as well as with control biopsies from a cohort of 19 patients diagnosed with gastritis without subsequent development of cancer. The presence of SPEM and intestinal metaplasia (IM) adjacent to and distant from the cancer was compared and spasmolytic polypeptide (SP) immunostaining within dysplastic/cancerous cells was identified. SPEM was present adjacent to cancer in all early cancer cases where the tumor was located in the body or at the body/antrum junction, and was present in the body mucosa distant from the cancer in 76% of cases. Intestinal metaplasia was found adjacent to the tumor in 76% of cases and in body sections in 52% of resections. SP immunostaining was noted within cancer cells in 62% of tumors, and within dysplastic cells in 76% of resections where dysplasia was present. SPEM was present in 82% of the biopsies obtained prior to the diagnosis of cancer, compared with only 37% in the gastritis cohort. IM was present in only 57% of biopsies. In conclusion, SPEM is strongly associated with early gastric cancers and is observed in gastric biopsies prior to the development of cancer. In addition, early gastric cancers demonstrated a high incidence of SP expression. These results suggest that SPEM merits consideration as an important pre-neoplastic gastric lesion.

metaplasia antralization spasmolytic peptide expression gastric adenocarcinoma trefoil proteins dysplasia pseudopyloric metaplasia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forman D, Sitas F, Newell DG, Stacey AR, Boreham J, Peto R, Campbell TC, Li J, Chen J: Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 46:608-611, 1990Google Scholar
  2. 2.
    Fox JG, Correa P, Taylor NS, Zavala D, Fontham E, Janney F, Rodriguez E, Hunter F, Diavolitsis S: Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol 84:775-781, 1989Google Scholar
  3. 3.
    Jaskiewicz K, Louwrens HD, Woodroof CW, Van Wyk MJ, Price SK: The association of Campylobacter pylori with mucosal pathological changes in a population at risk for gastric cancer. S Afr Med J 75:417-419, 1989Google Scholar
  4. 4.
    Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric cancer. N Engl J Med 325:1127-1131, 1991Google Scholar
  5. 5.
    Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, Sitas P: Association between infection with Helicobacter pylori and risk of gastric cancer. Evidence from a prospective investigation. Br J Med 302:1302-1305, 1991Google Scholar
  6. 6.
    Nomura A, Stemmerman GN, Chyou PH, Kato I, Perez GI, Blaser MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325:1132-1136, 1991Google Scholar
  7. 7.
    Peura DA: The report of the Digestive Health Initiative international update conference on Helicobacter pylori. Gastroenterology 113:S4-S8, 1997Google Scholar
  8. 8.
    Sipponen P, Marshall BJ: Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 29:579-592, 2000Google Scholar
  9. 9.
    Correa P: A human model of gastric carcinogenesis. Cancer Res 48:3554-3560, 1988Google Scholar
  10. 10.
    Smith VC, Genta RM: Role of Helicobacter pylori gastritis in gastric atrophy, intestinal metaplasia and gastric neoplasia. Microsc Res Tech 48:313-320, 2000Google Scholar
  11. 11.
    Haggit RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982-993, 1994Google Scholar
  12. 12.
    Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis: The updated Sydney system. Am J Surg Pathol 20:1161-1181, 1996Google Scholar
  13. 13.
    Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324-329, 1994Google Scholar
  14. 14.
    Kuipers EJ. Exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 13:3-11, 1999Google Scholar
  15. 15.
    Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, Goldenring JR: Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79:639-646, 1999Google Scholar
  16. 16.
    Yamaguchi H, Goldenring JR Kaminishi, M, Lee JR: Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 47:573-578, 2002Google Scholar
  17. 17.
    Wang TC, Goldenring JR, Dangler C, Ito S, Mueller A, Jeon WK, Koh TJ, Fox JG: Mice lacking secretory phospholipasa A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114:675-689, 1998Google Scholar
  18. 18.
    Goldenring JR, Ray GS, Coffey RJ, Meunier PC, Haley PJ, Barnes B, Car BD: Reversible drug-induced oxyntic atrophy in rats. Gastroenterology 118:1080-1093, 2000Google Scholar
  19. 19.
    Taupin T, Pederson J, Familari M, Cook G, Yeomans N, Giraud A: Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest 81:397-408, 2001Google Scholar
  20. 20.
    Wang TH, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118:36-47, 2000Google Scholar
  21. 21.
    Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR: Association of spasmolytic polypeptide expressing metaplasia (SPEM) with carcinogen administration and oxyntic atrophy in rats. Lab Invest 82:1045-1052, 2002Google Scholar
  22. 22.
    Ribieras S, Lefebvre O, Tomasetto C, Rio MC: Mouse trefoil factor genes: genomic organization, sequences and methylation analysis. Gene 266:67-75, 2001Google Scholar
  23. 23.
    Azarschab P, Al-Azzeeh E, Kornberger W, Gott P: Aspirin promotes TFF2 gene activation in human gastric cancer cell lines. FEBS Lett 488:206-210, 2001Google Scholar
  24. 24.
    Lefebcre O, Chenard MP, Masson R, Linares J, Dierich, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC: Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274:259-262, 1996Google Scholar
  25. 25.
    Park WS, Oh, RR, Park JY, Lee JH, Shin MS, Kim HS, Lee HK, Kim YS, Kim SY, Lee SH, Yoo NJ, Lee JY: Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119:691-698, 2000Google Scholar
  26. 26.
    Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK, Wang TC: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109:193-204, 2002Google Scholar
  27. 27.
    Wright NA, Pike C, Elia G: Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 343:82-85, 1990Google Scholar
  28. 28.
    Whitehead R: Gastrointestinal and Oesophageal Pathology. Edinburgh, Churchill Livingstone 1989, 411ppGoogle Scholar
  29. 29.
    Wong W-M, Garcia SB, Poulsom R, Goldenring JR, Wright NA: Aberrant spasmolytic polypeptide (TFF2)-expressing cell lineage (SPEM), pseudopyloric metaplasia (PPM) and the response to gastric mucosal damage. Gastroenterology 116:A525, 1999Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Anna Margrét Halldórsdóttir
  • Margrét Sigurdardóttir
  • Jón Gunnlaugur Jónasson
  • Margrét Oddsdóttir
  • Jónas Magnússon
  • Jeffrey R. Lee
  • James R. Goldenring

There are no affiliations available

Personalised recommendations